{"id":"dupilumab-dose-reduction","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Injection site reactions"},{"rate":"10-15","effect":"Conjunctivitis"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Oropharyngeal pain"},{"rate":"1-5","effect":"Herpes simplex infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammation. By blocking this receptor, it suppresses the production of IgE and inflammatory cytokines, reducing eosinophil recruitment and activation. This mechanism addresses the underlying pathophysiology of multiple type 2 inflammatory conditions including atopic dermatitis, asthma, and eosinophilic esophagitis.","oneSentence":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:09.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe atopic dermatitis"},{"name":"Moderate-to-severe asthma with type 2 inflammation"},{"name":"Chronic rhinosinusitis with nasal polyps"},{"name":"Eosinophilic esophagitis"},{"name":"Pruritus"}]},"trialDetails":[{"nctId":"NCT05369403","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-12-19","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT06116526","phase":"PHASE4","title":"Dupilumab De-escalation in Pediatric Atopic Dermatitis","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-04-01","conditions":"Atopic Dermatitis","enrollment":30},{"nctId":"NCT07091175","phase":"PHASE2","title":"Dupilumab Therapy in Nephrotic Syndrome in Children","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-11-27","conditions":"Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent","enrollment":66},{"nctId":"NCT06004986","phase":"PHASE4","title":"DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-08-14","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema","enrollment":216},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT05601882","phase":"PHASE3","title":"A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-11-28","conditions":"Atopic Dermatitis","enrollment":920},{"nctId":"NCT06818019","phase":"PHASE4","title":"Withdrawal of Dupilumab in Severe Asthma","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2025-04-02","conditions":"Severe Asthma","enrollment":205},{"nctId":"NCT05649579","phase":"","title":"Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2022-09-01","conditions":"Bullous Pemphigoid","enrollment":146},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dupixent"],"phase":"marketed","status":"active","brandName":"Dupilumab - Dose Reduction","genericName":"Dupilumab - Dose Reduction","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}